Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines

Jimin Hwang, Se Bee Lee, Seung Won Lee, Min Ho Lee, Ai Koyanagi, Louis Jacob, Kalthoum Tizaoui, Dong Keon Yon, Jae Il Shin, Lee Smith

Research output: Contribution to journalArticlepeer-review

30 Citations (Scopus)


Cerebral venous thrombosis (CVT) events have been reported after vaccination with adenoviral COVID-19 vector vaccines. This study aimed to compare the clinical presentations and courses of vaccine-induced thrombotic thrombocytopenia (VITT) between the two adenoviral vector vaccines, Ad26.COV.2.S (Janssen/Johnson & Johnson) and ChAdOx1 nCoV-19 (Astra-Zeneca). We found that CVT after Ad26.COV.2.S vaccination presents later with similar symptoms compared to CVT after administration of ChAdOx1 nCoV-19, albeit with more thrombosis and intracerebral hemorrhage, lower D-dimer and aPTT levels but similar mortality. These findings could help guide clinical assessment and management of CVT after COVID-19 vaccination.

Original languageEnglish
Article number102681
JournalJournal of Autoimmunity
Publication statusPublished - 2021 Aug

Bibliographical note

Funding Information:
We thank Elena Dragioti and Joaquim Radua for their valuable discussions and feedback.

Publisher Copyright:
© 2021 Elsevier Ltd

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines'. Together they form a unique fingerprint.

Cite this